MiNK Therapeutics (NASDAQ:INKT – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.12), Zacks reports.
MiNK Therapeutics Price Performance
INKT opened at $7.92 on Thursday. The company has a market capitalization of $31.39 million, a PE ratio of -2.03 and a beta of 0.16. The business has a 50-day moving average of $8.91 and a 200-day moving average of $7.75. MiNK Therapeutics has a fifty-two week low of $4.56 and a fifty-two week high of $19.00.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reissued a “buy” rating and set a $35.00 target price on shares of MiNK Therapeutics in a research note on Tuesday.
About MiNK Therapeutics
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.
Further Reading
- Five stocks we like better than MiNK Therapeutics
- Breakout Stocks: What They Are and How to Identify Them
- 3 Defense Stocks Set to Benefit From Increased Military Spending
- What Are Some of the Best Large-Cap Stocks to Buy?
- Aluminum Tariff Woes: Between 2 Stocks, 1 Shines Brighter
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Semtech Rallies on Earnings Beat—Is There More Upside?
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
